Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Brain+ AS's share price for the quarter that ended in Jun. 2025 was kr0.0154. Brain+ AS's Shares Outstanding (EOP) for the quarter that ended in Jun. 2025 was 1,132.94 Mil. Therefore, Brain+ AS's market cap for the quarter that ended in Jun. 2025 was kr17.45 Mil.
Brain+ AS's quarterly market cap
declined
from Jun. 2024 (kr20.74 Mil) to Dec. 2024 (kr19.94 Mil) and
declined
from Dec. 2024 (kr19.94 Mil) to Jun. 2025 (kr17.45 Mil).
Brain+ AS's annual market cap
declined
from Dec. 2022 (kr26.88 Mil) to Dec. 2023 (kr12.70 Mil) but then
increased
from Dec. 2023 (kr12.70 Mil) to Dec. 2024 (kr19.94 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Brain+ AS's Enterprise Value for Today is kr0.42 Mil.
Brain+ AS (OCSE:BRAINP) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Brain+ AS Market Cap Related Terms
Brain+ AS Market Cap Historical Data
* Premium members only.
The historical data trend for Brain+ AS's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:BRAINP vs VEEV, BTSG, TEM: Market Cap Comparison
For the Health Information Services subindustry, Brain+ AS's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brain+ AS Market Cap vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Brain+ AS's Market Cap distribution charts can be found below:
* The bar in red indicates where Brain+ AS's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Brain+ AS's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brain+ AS (OCSE:BRAINP) has a Market Cap of kr4.76 Mil as of Jul. 13, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Brain+ AS and its competitors.
Is Brain+ AS's Market Cap too high?
Brain+ AS's current Market Cap is kr4.76 Mil.
How does Brain+ AS's Market Cap compare to VEEV and BTSG?
Brain+ AS's Market Cap of kr4.76 Mil can be compared against companies in the Healthcare Providers & Services industry. The industry median Market Cap is 101.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Healthcare Providers & Services company?
The median Market Cap among Healthcare Providers & Services companies is 101.86, based on 697 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Brain+ AS and its competitors. For the Healthcare Providers & Services industry, the median Market Cap is 101.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Brain+ AS's current Market Cap is kr4.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brain+ AS stock overvalued right now?
Brain+ AS (OCSE:BRAINP) has a current Market Cap of kr4.76 Mil. The current Market Cap is kr4.76 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Brain+ AS (OCSE:BRAINP), the current Market Cap is kr4.76 Mil as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Brain+ AS is a digital therapeutics company. It is focused on developing and commercializing solutions for dementia care and with a primary focus on Cognitive Stimulation Therapy (CST). The company has developed a set of Digital Medicine technologies. Its product pipeline includes CST Therapist Companion, and CST Home Companion; CST Home Care; CST for Mild Cognitive Impairment (MCI). The company is developing Ayla, a scalable dementia care platform that provides software-based therapy and care solutions designed to support individuals with dementia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:BRAINP has been successfully added to your 